Most Recent
Biotech files new patent suit against Samsung Bioepis over Crohn’s drug
Intellectual Property 2024-09-26 11:55 pm By Sam Matthews Melbourne
Samsung Bioepis can't get indemnity costs from Janssen Biotech after it surrendered patents for Crohn’s disease drug Stelara and filed a fresh case based on new patents for the drug. 
Samsung Bioepis sues Janssen Biotech to invalidate Stelara patents
Intellectual Property 2024-02-08 11:48 pm By Christine Caulfield
South Korean biosimilars company Samsung Bioepis has sued Johnson & Johnson's Janssen Biotech to invalidate two patents for Crohn's disease drug Stelara, after reaching a licencing agreement over the medicine in the US.